{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:53:46Z","timestamp":1761224026983,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.drudis.2016.07.009","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T11:35:05Z","timestamp":1469187305000},"page":"1820-1827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Triple inhaled therapy for chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Paolo","family":"Montuschi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Malerba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Macis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Mores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2015","series-title":"Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease","author":"Global initiative for chronic obstructive pulmonary disease (GOLD)","key":"10.1016\/j.drudis.2016.07.009_bib0305"},{"key":"10.1016\/j.drudis.2016.07.009_bib0310","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.arbres.2012.04.001","article-title":"Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD","volume":"48","author":"Miravitlles","year":"2012","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.drudis.2016.07.009_bib0315","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bcpt.12366","article-title":"Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the Finnish guidelines","volume":"116","author":"Kankaanranta","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"Suppl B","key":"10.1016\/j.drudis.2016.07.009_bib0320","first-page":"5","article-title":"Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease \u2013 2007 update","volume":"14","author":"O\u2019Donnell","year":"2007","journal-title":"Can. Respir. J."},{"year":"2009","series-title":"Guidelines for the diagnosis and treatment of COPD","author":"Nagai","key":"10.1016\/j.drudis.2016.07.009_bib0325"},{"key":"10.1016\/j.drudis.2016.07.009_bib0330","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1183\/13993003.01170-2015","article-title":"A review of national guidelines for management of COPD in Europe","volume":"47","author":"Miravitlles","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.drudis.2016.07.009_bib0335","first-page":"2207","article-title":"The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK","volume":"10","author":"Brusselle","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.drudis.2016.07.009_bib0340","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.drudis.2014.08.004","article-title":"Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping","volume":"19","author":"Montuschi","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2016.07.009_bib0345","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/thx.2004.032516","article-title":"Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease","volume":"60","author":"Brightling","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2016.07.009_bib0350","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1183\/09031936.06.00072105","article-title":"Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment","volume":"27","author":"Leigh","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.drudis.2016.07.009_bib0355","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","article-title":"Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial","volume":"356","author":"Brightling","year":"2000","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2016.07.009_bib0360","first-page":"146","article-title":"Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review","volume":"6","author":"Papaiwannou","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.drudis.2016.07.009_bib0365","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0370","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0375","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.750","article-title":"Role of tiotropium in reducing exacerbations of chronic obstructive pulmonary disease when combined with long-acting \u03b22-agonists and inhaled corticosteroids: the Outpul study","author":"Ferroni","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2016.07.009_bib0380","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1021\/jm5013227","article-title":"Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends","volume":"58","author":"Montuschi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2016.07.009_bib0385","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2174\/0929867311320120002","article-title":"Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD","volume":"20","author":"Montuschi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2016.07.009_bib0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pharmthera.2015.09.004","article-title":"Research and development of bronchodilators for asthma and COPD with a focus on G protein\/KCa channel linkage and \u03b22-adrenergic intrinsic efficacy","volume":"156","author":"Kume","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.07.009_bib0395","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.coph.2014.03.005","article-title":"Crosstalk between \u03b22-adrenoceptor and muscarinic acetylcholine receptors in the airway","volume":"16","author":"Pera","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.drudis.2016.07.009_bib0400","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/pats.200504-043SR","article-title":"Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease","volume":"2","author":"Belmonte","year":"2005","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.drudis.2016.07.009_bib0605","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2013.01.054","article-title":"A role for M2 and M3 muscarinic receptors in the contraction of rat and human small airways","volume":"702","author":"Brown","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2016.07.009_bib0405","doi-asserted-by":"crossref","first-page":"e87443","DOI":"10.1371\/journal.pone.0087443","article-title":"Steroid resistance in COPD? Overlap and differential anti-inflammatory effects in smokers and ex-smokers","volume":"9","author":"Hoonhorst","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2016.07.009_bib0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2016.01.002","article-title":"Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease","volume":"37","author":"Jiang","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.07.009_bib0415","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b22 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2016.07.009_bib0420","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","article-title":"Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease","volume":"131","author":"Barnes","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.drudis.2016.07.009_bib0425","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa041892","article-title":"Decreased histone deacetylase activity in chronic obstructive pulmonary disease","volume":"352","author":"Ito","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0430","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0435","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0440","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15412555.2015.1034256","article-title":"Efficacy and safety of umeclidinium added to fluticasone propionate\/salmeterol in patients with COPD: results of two randomized, double-blind studies","volume":"13","author":"Siler","year":"2015","journal-title":"COPD"},{"key":"10.1016\/j.drudis.2016.07.009_bib0450","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40265-015-0532-5","article-title":"Inhaled umeclidinium in COPD patients: a review and meta-analysis","volume":"76","author":"Pleasants","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2016.07.009_bib0455","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-014-0186-8","article-title":"Umeclidinium\/vilanterol: first global approval","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2016.07.009_bib0460","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40265-015-0354-5","article-title":"Fluticasone furoate\/vilanterol: a review of its use in patients with asthma","volume":"75","author":"Syed","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2016.07.009_bib0465","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-014-0269-6","article-title":"Fluticasone furoate\/vilanterol: a review of its use in chronic obstructive pulmonary disease","volume":"74","author":"McKeage","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2016.07.009_bib0470","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1021\/jm800279t","article-title":"X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain","volume":"51","author":"Biggadike","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2016.07.009_bib0475","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1465-9921-8-54","article-title":"Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate","volume":"8","author":"Valotis","year":"2007","journal-title":"Respir. Res."},{"key":"10.1016\/j.drudis.2016.07.009_bib0480","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1060028013512615","article-title":"Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease","volume":"48","author":"Bollmeier","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.drudis.2016.07.009_bib0485","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5414\/CP202390","article-title":"Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers","volume":"53","author":"Brealey","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.07.009_bib0490","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0615","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD","volume":"12","author":"Crim","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.drudis.2016.07.009_bib0500","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia","volume":"68","author":"Suissa","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2016.07.009_bib0505","doi-asserted-by":"crossref","first-page":"d3215","DOI":"10.1136\/bmj.d3215","article-title":"Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials","volume":"342","author":"Singh","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2016.07.009_bib0510","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thoraxjnl-2012-201926","article-title":"Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials","volume":"68","author":"Dong","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.drudis.2016.07.009_bib0515","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0520","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1314411","article-title":"Tiotropium and the risk of death in COPD","volume":"370","author":"Loke","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0525","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1021\/jm501915g","volume":"58","author":"Hughes","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2016.07.009_bib0530","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1016\/j.bmcl.2015.10.008","article-title":"Molecular hybridization yields triazole bronchodilators for the treatment of COPD","volume":"25","author":"Jones","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2016.07.009_bib0535","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1021\/la302281n","article-title":"Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers","volume":"28","author":"Vehring","year":"2012","journal-title":"Langmuir"},{"key":"10.1016\/j.drudis.2016.07.009_bib0540","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.pupt.2013.03.015","article-title":"Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD","volume":"26","author":"Bateman","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.07.009_bib0620","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.pupt.2013.03.009","article-title":"Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD","volume":"26","author":"Norris","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2016.07.009_bib0550","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/jpet.114.216861","article-title":"Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and \u03b22-adrenoceptor agonist properties","volume":"351","author":"Hedge","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2016.07.009_bib0555","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/cpdd.105","article-title":"Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist \u03b22-agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers","volume":"3","author":"Norris","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.drudis.2016.07.009_bib0560","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.113.210997","article-title":"The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting \u03b22-adrenoceptor agonist","volume":"349","author":"Tannheimer","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2016.07.009_bib0565","doi-asserted-by":"crossref","first-page":"e00046","DOI":"10.1002\/prp2.46","article-title":"The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting \u03b22-adrenoceptor agonist in preclinical animal species","volume":"2","author":"Salmon","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.drudis.2016.07.009_bib0570","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000315416","article-title":"Inhaled corticosteroids in COPD: a controversy","volume":"80","author":"Barnes","year":"2010","journal-title":"Respiration"},{"key":"10.1016\/j.drudis.2016.07.009_bib0575","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1513\/AnnalsATS.201411-501OC","article-title":"A mixed phenotype of airway wall thickening and emphysema is associated with dyspnea and hospitalization for chronic obstructive pulmonary disease","volume":"12","author":"Van Tho","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.drudis.2016.07.009_bib0580","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0585","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MCP.0000000000000238","article-title":"Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype","volume":"22","author":"Russell","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.drudis.2016.07.009_bib0590","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1186\/s12864-015-2170-4","article-title":"Integrative phenotyping framework (iPF): integrative clustering of multiple omics data identifies novel lung disease subphenotypes","volume":"16","author":"Kim","year":"2015","journal-title":"BMC Genomics"},{"key":"10.1016\/j.drudis.2016.07.009_bib0625","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.drudis.2016.07.009_bib0600","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/15412555.2013.814626","article-title":"Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study","volume":"10","author":"Beier","year":"2013","journal-title":"COPD"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644616302598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644616302598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:28:21Z","timestamp":1761222501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644616302598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1359644616302598"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2016.07.009","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple inhaled therapy for chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2016.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}